Weibull and exponential proportional hazard modelling for optimizing economic evaluations of cancer treatments: FOLFIRINOX (FFX) vs gemcitabine (GEM) in metastatic pancreas cancer (mPC).

• DOI: 10.1200/jco.2016.34.15_suppl.e15704
• Publication Date: 2018-09-06T16:29:31Z
• Authors: Mahdi Gharaibeh; Hitendra Patel; Ali McBride; J. Lyle Bootman; Ivo Abraham
• Keywords: 03 medical and health sciences; 0305 other medical science; 3. Good health

e15704Background: Classical pharmacoeconomic analysis methods may prove insufficient for the economic evaluation of novel cancer treatments, esp. in advanced/metastatic setting as it is important to calculate a reliable and credible estimation of the total cost and outcomes. The application of different parametric models may impact economic evaluation estimates. Access to individual patient data from randomized controlled (RCT) trials is limited, hence digitization software is used to reproduce published Kaplan-Meier (K-M) curves and estimate distribution parameters. We compared the application of Weibull and exponential proportion hazard models to economic evaluation studies for FFX v. GEM in mPC. Methods: Weibull and exponential regressions were applied to progression-free (PFS) and overall (OS) survival data from digitization to derive the lambda and gamma parameters for Weibull and exponential models. Curves were estimated for FFX OS and PFS. Model selection was based on the value of R2and residual su...